Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 2026 → Sep 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 2026 to Sep 2027
    • Eligibility criteria expanded, about 53 words
  2. Primary and study completion dates: Sep 2025 to Sep 2026v12
  3. Re-verified, no change to tracked fieldsv11
  4. Primary and study completion dates: Sep 2024 to Sep 2025v10
  5. Primary and study completion dates: Sep 2023 to Sep 2024
    • Study sites revised (7)
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 50 to confirmed 24
    • Site details revised at 7 of 7 sites
    v7
  3. Primary and study completion dates: Sep 2022 to Sep 2023v6
  4. Eligibility criteria expanded, about 35 wordsv5
  5. Primary and study completion dates: Sep 2021 to Sep 2022v4
  6. Re-verified, no change to tracked fieldsv3
  7. Study sites: 1 to 7
    • Eligibility criteria revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.
Trial Details
NCT Number NCT04106414
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Bristol-Myers Squibb
Conditions
(from sponsor)		 Endometrial Adenocarcinoma, Endometrial Carcinosarcoma
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov